Especially SNAP-25 may have value as either prognostic biomarker in predementia stages of AD, or predictive biomarker in trials, while others such as NPTX-2 or 14-3-3 proteins may serve as surrogate outcome measures in trials, ideally as blood-based biomarkers.49 This evidence concerns the gene NPTX2 and Alzheimer disease.